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Cyclophosphamide induces dose- and time-dependent elevations in spleen
norepinephrine levels of BALB/c mice
Jonathan D.Karp
Jennifer L.Szczytkowski
Abstract

Chemotherapeutic drugs may not only kill rapidly dividing cells but may also alter the
extracellular environment of surviving cells. We investigated the possibility that
cyclophosphamide might alter the noradrenergic environment of the spleen. Male BALB/cByJ
mice were administered a single injection of cyclophosphamide (0, 15, 50, or 100 mg/kg).
Seventy-two hours after injection animals receiving 50 or 100 but not 15 mg/kg experienced
elevated norepinephrine concentrations (pmol/mg) compared to animals given 0 mg/kg. The time
course of changes in norepinephrine concentration was investigated 24–216 h after
administration of 50 mg/kg cyclophosphamide; norepinephrine took 48 h to elevate, remained
elevated for 48–96 h, and returned to vehicle-treated levels by 120 h. Cyclophosphamide in both
experiments reduced spleen mass but did not alter total norepinephrine/spleen. These results
suggest that low doses of cyclophosphamide can increase the norepinephrine available to
influence cell–cell interactions in the spleen.
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The integration of nervous and immune system function is an important component for
understanding susceptibility to disease. Through innervation of immune organs and shared
chemical messengers, the nervous system influences the cells that are involved in generating
immune responses. Sympathetic nervous system innervation of lymphoid organs provides a
direct and rapid route for the central nervous system to influence the immune system [2], [14].
Neurochemicals released by sympathetic nervous system activity include norepinephrine,
substance P, neuropeptide Y, vasoactive intestinal peptide, somatostatin, purines, and calcitonin
gene-related peptide, among others [2], [7]. Norepinephrine is recognized as one of the most
relevant to neuroimmunomodulation [7], [12], [14]. Norepinephrine is among the
neurochemicals localized in the nerve fibers of lymphoid organs, noradrenergic receptors are
found on many types of immune cells, and removal of norepinephrine-producing nerve fibers
changes characteristics of immune responses [2], [14]. Comprehensive reviews indicate that
sympathetic nervous system manipulations and norepinephrine can either stimulate or inhibit
specific immune parameters depending upon the immune status of the subject, the type and dose
of antigen used to activate the immune system, the type of animal studied, and the timing of
antigen exposure relative to sympathetic nervous system activation [7], [12], [16], [17]. Indeed,
understanding effects of norepinephrine on the immune system is significant because
pharmacological manipulation of sympathetic nervous system activity is commonly used in
clinical medicine [17].

An examination of changes in norepinephrine content following cyclophosphamide
treatment is warranted because cyclophosphamide is used as part of the therapy for autoimmune
disorders (such as lupus erythematosus, chronic polyarthritis, myasthenia gravis), as part of
chemotherapeutic treatments for some malignant tumors (e.g. non-Hodgkin's lymphoma,
metastatic breast cancer, lymphatic leukemia), and for preventing rejection after organ or bone
marrow transplantation [1], [18]. Cyclophosphamide is used clinically because the drug and its
metabolites are antineoplastic [13]. The antineoplastic effects of cyclophosphamide and its
metabolites might occur not only because of direct alkylation of DNA but also because these
drugs change the neurochemical milieu in which surviving cells interact. For instance, alterations
in norepinephrine concentration as a result of cyclophosphamide administration could directly or
indirectly influence cyclophosphamide-mediated cytotoxicity and/or could alter signaling
between the nervous system and the immune system.

The spleen was selected as the initial place to study the effects of cyclophosphamide on
norepinephrine concentration because the spleen functions as an interface between the nervous
system and the immune system [7], [9]. Removal of sympathetic innervation of the spleen blocks
the ability of behavioral conditioning to prolong heart allograft survival [8], attenuates the effects
of stress exposure on antibody production [19], and alters some but not all characteristics of an
immune response [3].

Male BALB/cByJ mice (aged 3–5 weeks, The Jackson Labs, Bar Harbor, ME) were used
in these experiments. Mice were housed 3–5/cage in standard shoe box cages for 3–4 weeks prior
to the start of the experiments. Food and water were available at all times. All the mice in a

single cage always received the same treatment. All procedures were approved by the Rider
University Institutional Animal Care and Use Committee in accordance with the regulations of
the Animal Welfare Act.

Cyclophosphamide (Sigma-Aldrich, St. Louis, MO) was solubilized in ethanol and
administered i.p. (in 500 μl of sterile filtered (0.1 μ) phosphate buffered saline, GIBCO,
Carlsbad, CA). Vehicle-treated animals received an equal volume of the phosphate buffered
saline–ethanol solution. Spleens were harvested, weighed, and frozen on dry ice, and stored at
−80 °C until assay. The norepinephrine content of spleen samples was measured by highperformance liquid chromatography (HPLC) with electrochemical detection. Briefly, samples
(50–75 mg wet weight) were sonicated in 0.1 M HClO4 (10 μl/mg tissue) spiked with an internal
standard of 3,4-dihydroxybenzylamine (final concentration 0.25 μM). Homogenates were
centrifuged and aliquots of the supernatants were combined with 1 ml of sodium phosphate
buffer (pH 6.1) and 1 ml 1.5 M Tris/EDTA buffer (pH 8.6). Acid-washed alumina (50 mg) was
added to each sample and norepinephrine was extracted by shaking for 5 min. The alumina was
washed twice with distilled water, placed into a clean microfilter and the water was removed by
centrifugation. Norepinephrine was eluted off the alumina by adding 0.1 M HClO4 to the
microfilter and centrifugation was used to collect the extract in a new microcentrifuge tube. For
each sample, extract (20 μl) was manually injected into the HPLC.

The HPLC system consisted of programmable pumps (Varian ProStar) and a C18
reverse-phase column (150 mm×4.6, 5 μ) located in temperature controlled housing (27 °C) with
the electrochemical detector (Varian Star 9080). The system was operated at a flow rate of 1.0

ml/min with the detector potential set at 0.75 V versus an Ag-AgCl reference electrode. The
mobile phase buffer consisted of 0.33 M citrate, 0.67 M phosphate (pH 4.5) with sodium octyl
sulfate (1.2 mM) and 12% methanol. The signal from the detector was recorded by a PC
computer (Dell Optiplex) running Windows98 fitted with an ADC controller card using Varian
Star Chromatography software (Star Chromatography, version 5). The software measured the
area under each peak and compared the value obtained to the internal standard (5 pmol of 3,4dihydroxybenzylamine). All data were evaluated initially by ANOVA followed by the Student–
Newman–Keuls post-hoc test (Statview version 5.0, SAS Institute Inc., Cary, NC) on a PC
computer. Treatment effects were considered statistically significant at P<0.05.

To investigate the effects of cyclophosphamide on the noradrenergic environment of the
spleen, mice were administered a single injection of cyclophosphamide (15, 50, or 100 mg/kg) or
vehicle. Data analysis from spleens harvested 72 h after injection revealed dose-dependent
changes in spleen mass and in norepinephrine content per mg spleen; cyclophosphamide induced
a reduction in spleen mass (Fig. 1A, F3,32=13.3, P<0.001) and an elevation in spleen
norepinephrine content (Fig. 1B, F3,32=20.2, P<0.001). For both measures, post-hoc analysis
revealed that vehicle-treated spleens were not different from spleens exposed to 15 mg/kg while
the 50 and 100 mg/kg groups were statistically different from the vehicle treatment. Total spleen
norepinephrine content (calculated as spleen mass×norepinephrine/mg) was not influenced by
cyclophosphamide treatment (Fig. 1C, dose effect, P=0.08).
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Fig. 1. Dose-dependent effects of cyclophosphamide on spleen mass (A), spleen
norepinephrine content (B), and total norepinephrine per spleen (C). Spleens from mice injected
with cyclophosphamide (0, 15, 50, or 100 mg/kg) were collected 72 h after injection. The
number of mice in each group is indicated within each bar. The * indicates a statistical difference
(P<0.05) from the 0 mg/kg group.

To investigate the time course of cyclophosphamide-mediated changes in spleen mass
and norepinephrine concentration, mice were injected with 50 mg/kg cyclophosphamide and
spleen samples were collected 24, 48, 72, 96, 120, 168, or 216 h after injection. ANOVA
revealed a dose×time interaction (Fig. 2A, F6,106=29.3, P<0.001); post-hoc comparisons
showed that mice administered cyclophosphamide displayed reductions in spleen mass compared
to vehicle-treated mice 24, 48, 72, and 96 h after injection. Evaluation of changes in spleen
norepinephrine content also revealed a dose×time interaction (Fig. 2B, F6,106=2.3, P=0.04);
post-hoc analysis showed that spleen norepinephrine concentrations were elevated in
cyclophosphamide-treated mice compared to vehicle-treated mice 48, 72, and 96 h after
injection. At no time after injection was the total amount of norepinephrine per spleen different
between vehicle- and cyclophosphamide-treated mice (Fig. 2C, time×dose, P=0.77).
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Fig. 2. Time-dependent effects of cyclophosphamide on spleen mass (A), spleen
norepinephrine content (B), and total norepinephrine per spleen (C). Mice were injected with 0
or 50 mg/kg cyclophosphamide and spleens were harvested 24, 48, 72, 96, 120, 168, or 216 h

after injection. There were 8, 9, 11, 7, 7, 8, and 6 mice administered the 0 mg/kg dose and 9, 10,
14, 8, 7, 8, and 8 mice administered 50 mg/kg cyclophosphamide at each time point,
respectively. The * indicates a statistical difference (P<0.05) from the 0 mg/kg group at the
indicated time point.

These results suggest that cyclophosphamide or one of its in vivo metabolites [13]
induces dose- and time-dependent elevations in norepinephrine content per mg spleen.
Interestingly, reductions in spleen mass were not always associated with elevations in spleen
norepinephrine content; at 24 h a decrease in spleen mass was observed without a concomitant
elevation in spleen norepinephrine content (Fig. 2A,B). The total amount of norepinephrine in
the spleen did not vary as a result of cyclophosphamide administration (Fig. 1, Fig. 2) suggesting
that sympathetic activity in the spleen compensated for or was unaffected by the changes in
cellularity induced by cyclophosphamide [4]. Cyclophosphamide may also alter norepinephrine
turnover in the spleen but the current experiments were not designed to address this possibility.
The migration of lymphocytes into the peripheral circulation is a well-known effect of
norepinephrine [12], [14] and it is possible, though not proven here, that norepinephrine
stimulated cell migration from the spleen and that such a migration could be responsible for
reductions in spleen mass. Cyclophosphamide-mediated reductions in spleen mass might also
occur from a transient drug-induced inhibition of spleen cell proliferation or from changes in
norepinephrine metabolism in the spleen. Additional experiments are needed to address these
possibilities. Irrespective of the mechanism, it is clear that cyclophosphamide administration
does make more norepinephrine available in the spleen to influence cell activity.

Reductions in spleen mass, elevations in spleen norepinephrine content, and a lack of
change in the total norepinephrine per spleen are consistent with an earlier report [4]. The current
experiments extend these findings to a different mouse strain (BALB/cByJ versus C3H/HeJ)
using a different range of cyclophosphamide doses (0, 15, 50, and 100 mg/kg compared to 50
and 250 mg/kg). The dose range used in the current experiments also establishes a threshold for
cyclophosphamide-mediated changes in spleen norepinephrine (between 15 and 50 mg/kg).
Finally, the current studies describe the kinetics for cyclophosphamide-mediated changes in the
spleen (from 24 to 216 h after injection) whereas the earlier report examined only a single time
point (48 h after injection).

In regard to immunity, there is an emerging literature indicating that cyclophosphamide is
potentially immunomodulatory. Sympathetic nerve fibers increase in density around arterioles of
the spleen after cyclophosphamide administration [4] and maintain organ norepinephrine levels
even as the number of lymphocytes in the spleen is decreased [4]. The spleens of
cyclophosphamide-treated mice develop early myeloid cells capable of producing large amounts
of nitric oxide from T cell-derived signals [15]. Cyclophosphamide can also alter the cell surface
markers of immune cells in the marginal zone of the spleen [20]. In addition, aged mice treated
with cyclophosphamide exhibit increased numbers of immune cells with a ‘young-like’ profile of
cell proliferation and antibody responses [10]. Functionally, cyclophosphamide can increase or
decrease delayed type hypersensitivity responses depending on the dose administered and on the
timing of its administration relative to antigen exposure [5], [6]. What role, if any,
cyclophosphamide-induced changes in norepinephrine have on specific cells or immune effector
responses remains to be determined. Interestingly, we observed that a dose of cyclophosphamide

that did not elevate spleen norepinephrine levels (15 mg/kg, Fig. 1) and did not alone influence
antibody production [11] was able to augment antibody production when administered in
combination with a psychological stressor (restraint) that presumably activates the sympathetic
nervous system [11]. Such observations imply that cyclophosphamide can influence interactions
between immunological, neurochemical, and behavioral manipulations.

Observations that cyclophosphamide alters the noradrenergic environment of the spleen
are intriguing because subjects administered chemotherapeutic agents such as cyclophosphamide
may be more susceptible to opportunistic infections, not only because the drug alkylates the
DNA of mitogenic cells, but also because the drug alters the neurochemical milieu in which
immune responses occur. As norepinephrine is a major immunomodulatory product of the
sympathetic nervous system that is known to be involved in lymphocyte proliferation, cytokine
production, and migratory behavior of immune cells [7], [12], [16], [17], it is possible that
cyclophosphamide-mediated changes in norepinephrine could impact upon the ability of the
immune system to successfully combat infectious agents. Some have suggested that
norepinephrine could stimulate humoral immunity by simultaneously augmenting antibody
production by B cells and inhibiting cytokine production that would stimulate cell-mediated
immune processes [7], [12], [16], [17].

In the future, it will be important to ascertain if cyclophosphamide effects on
norepinephrine concentrations are limited to tissues where cells of the immune system interact
and if all tissues innervated by the sympathetic nervous system are influenced by
cyclophosphamide in the same way as the spleen. Similarly, as the nervous system and the

immune system are engaged in reciprocal communication, it will be of interest to examine the
central nervous system consequences of peripheral cyclophosphamide administration.
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